Alliancebernstein L.P. decreased its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 13.6% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 116,911 shares of the biopharmaceutical company’s stock after selling 18,400 shares during the period. Alliancebernstein L.P.’s holdings in Celldex Therapeutics were worth $422,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in CLDX. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Celldex Therapeutics by 26.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,885 shares of the biopharmaceutical company’s stock worth $104,000 after buying an additional 6,000 shares in the last quarter. Hikari Power Ltd bought a new stake in shares of Celldex Therapeutics during the first quarter worth about $181,000. American International Group Inc. boosted its stake in shares of Celldex Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 58,838 shares of the biopharmaceutical company’s stock worth $212,000 after buying an additional 3,880 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Celldex Therapeutics by 2.2% in the first quarter. Parametric Portfolio Associates LLC now owns 65,884 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 1,409 shares in the last quarter. Finally, Creative Planning boosted its stake in shares of Celldex Therapeutics by 6.1% in the first quarter. Creative Planning now owns 71,420 shares of the biopharmaceutical company’s stock worth $258,000 after buying an additional 4,084 shares in the last quarter. Institutional investors own 65.83% of the company’s stock.

Celldex Therapeutics, Inc. (CLDX) traded up 1.65% during midday trading on Friday, reaching $2.47. The company had a trading volume of 138,946 shares. The firm’s market capitalization is $309.01 million. The stock’s 50 day moving average is $2.47 and its 200 day moving average is $3.01. Celldex Therapeutics, Inc. has a 12-month low of $2.20 and a 12-month high of $5.02.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.05. The business had revenue of $3.83 million for the quarter, compared to analyst estimates of $1.21 million. Celldex Therapeutics had a negative return on equity of 51.87% and a negative net margin of 1,318.94%. Celldex Therapeutics’s quarterly revenue was up 175.5% compared to the same quarter last year. During the same period last year, the company posted ($0.32) earnings per share. Equities research analysts expect that Celldex Therapeutics, Inc. will post ($1.05) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Alliancebernstein L.P. Has $422,000 Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/11/alliancebernstein-l-p-has-422000-stake-in-celldex-therapeutics-inc-nasdaqcldx.html.

A number of brokerages have recently issued reports on CLDX. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, August 1st. Jefferies Group LLC reiterated a “hold” rating and set a $3.50 price objective (down previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, May 11th. Zacks Investment Research cut Celldex Therapeutics from a “buy” rating to a “sell” rating in a research note on Monday, July 17th. Aegis reiterated a “buy” rating on shares of Celldex Therapeutics in a research note on Thursday, June 29th. Finally, Cowen and Company reiterated a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, June 6th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $7.32.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX).

Institutional Ownership by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.